February 23, 2017 / 10:22 AM / 9 months ago

BRIEF-GSK reports positive results in study for controlled asthma

Feb 23 (Reuters) - GlaxoSmithKline Plc:

* Positive results for Relvar Ellipta lung function study in patients with well-controlled asthma

* Patients randomised to FF/VI taken once-daily maintained lung function versus those randomised to twice-daily FP/SAL, meeting study’s primary endpoint

* GSK now intends to submit this data to European Medicines Agency (EMA)

* Incidences of on-treatment serious adverse events and adverse events of special interest were consistent with known safety profile of FF/VI, Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below